Treatment of diarrhea associated with Clostridioides difficile.
Elimination of diarrhea caused by Clostridioides difficile.
Absorption: Minimal systemic absorption.
Distribution: Stays primarily in the GI tract.
Metabolism and Excretion: Mostly transformed via hydrolysis in the GI tract to OP-1118, its active metabolite. Eliminated mostly (>92%) in feces: <1% excreted in urine.
Half-life: Fidaxomicin– 11.7 hr; OP-1118– 11.2 hr.
Use Cautiously in:
GI: GI HEMORRHAGE, nausea, abdominal pain
Hemat: anemia, neutropenia
Misc: HYPERSENSITIVITY REACTIONS (INCLUDING ANGIOEDEMA)
* CAPITALS indicate life-threatening.
Underline indicate most frequent.
PO (Adults): 200 mg twice daily for 10 days .
PO (Children ≥6 mo and ≥12.5 kg): Tablets– 200 mg twice daily for 10 days (if unable to swallow tablets, use granules for oral suspension).
PO (Children ≥6 mo and 9–<12.5 kg): Granules for oral suspension– 160 mg twice daily for 10 days.
PO (Children ≥6 mo and 7–<9 kg): Granules for oral suspension– 120 mg twice daily for 10 days.
PO (Children ≥6 mo and 4–<7 kg): Granules for oral suspension– 80 mg twice daily for 10 days.
Granules for oral suspension (berry-flavor): 200 mg/5 mL
Tablets: 200 mg
Lab Test Considerations:
May cause ↑ serum alkaline phosphatase, and hepatic enzymes.
Administer twice daily, about 12 hr apart, without regard to food.
Decrease in diarrhea caused by Clostridioides difficile.
The Washington Manual of Medical Therapeutics helps you diagnose and treat hundreds of medical conditions. Consult clinical recommendations from a resource that has been trusted on the wards for 50+ years. Complete Product Information.